ClinicalTrials.gov posted results on 1 September 2026 for a completed Phase 2 study of pembrolizumab, also known as Keytruda, with paclitaxel and olaparib in previously treated advanced gastric adenocarcinoma. The trial enrolled 19 participants and reported median overall survival of 9.5 months in the measurable-disease group and 7.6 months in the unmeasurable-disease group.

Background

The study evaluated paclitaxel plus olaparib and pembrolizumab in patients with previously treated advanced gastric cancer. Its stated purpose was to assess the regimen’s safety and clinical activity. The registry listed advanced gastric adenocarcinoma as the condition and paclitaxel, olaparib, and pembrolizumab as the interventions.

Trial design

This was a completed Phase 2 study identified as NCT04209686, with 19 participants enrolled. The brief study title described treatment with paclitaxel, pembrolizumab, and olaparib in previously treated advanced gastric adenocarcinoma.

The supplied record did not include primary outcome entries or statistical analyses. Reported measurements were organized by groups identified as “Arm1 - Measurable Disease” and “Arm 2-Unmeasurable Disease.”

Key results

  • Median overall survival was 9.5 months in Arm 1, the measurable-disease group.
  • Median overall survival was 7.6 months in Arm 2, the unmeasurable-disease group.
  • Grade 3 or above study drug-related adverse events were reported in 7 participants in the measurable-disease group and 0 participants in the unmeasurable-disease group.
  • Immune-related adverse events were reported in 6 participants in the measurable-disease group and 1 participant in the unmeasurable-disease group.

The record supplied no numerical values for the listed 95% confidence intervals, and no p-values, response data, or comparative statistical analyses were provided.

What this means

The posted results provide survival medians and adverse-event counts for a small, completed study of pembrolizumab with paclitaxel and olaparib in previously treated advanced gastric adenocarcinoma. The two groups were reported according to measurable- or unmeasurable-disease status, so the supplied data do not establish a treatment comparison between them.

The findings document overall survival and selected safety measurements but do not, on their own, establish the regimen’s comparative efficacy, statistical significance, or a change to pembrolizumab’s indication.

Source

Source: ClinicalTrials.gov, registry results for “Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma,” NCT04209686, posted on 1 September 2026. The record is available at clinicaltrials.gov/study/NCT04209686.